Prognostic Significance of KRG Gene Rearrangement and Protein Expression in Prostate Cancer

PAN Xiu-yi, TAN Jun-ya, NIE Ling. et al

Abstract

To investigate gene rearrangement and protein expression of ETS related gene (ERG ) in prostate cancer of Chinese patients and its correlation with clinicopathological characteristics and prognosis. Methods This study collected 482 cases of prostatic adenocarcinomas diagnosed by prostate biopsy in West China Hospital of Sichuan University from 2009 to 2014. Fluorescencein situ hybridization (FISH) and immuno-histochemical staining (IHC) were performed to access the ERG rearrangement and protein expression respectively. Relationship between ERG rearrangement and protein expression was assessed by Spearman rank order correlation. The correlations of ERG rearrangement and protein expression with clinicopathological variables and prognosis were further analyzed. Results ERG rearrangement was detected in 87 (18.0 %) cases, of which 45 (51.7%) was translocation and 42 (48.3%) was deletion. ERG protein expression was detected in 74 (15.4%) cases. Follow-up data was obtained in 368 cases. ERG rearrangement and protein expression had no correlations to age, Gleason score and pre-operation PSA level ( P>0.05), but ERG protein level was decreased in metastatic cases or castration resistant prostate cancer (CRPC) cases （ PERG rearrangement, as well as ERG protein expression, could not serve as an independent prognostic biomarker.

Keywords: Prostate cancer, ERG, Gene rearrangement, Protein expression, Prognosis 

 

Full Text:

PDF


References


TOMLINS SA, RHODES DR, PERNER S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science,2005,310(5748) ;644-648.

HAN B, MEHRA R, DHANASEKARAN SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5- ETVl fusion protein in prostate cancer. Cancer Res,2008,68 (18):7629-7637.

PFLUEGER D. RICKMAN DS, SBONER A, etui. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia, 2009 .11(8): 804-811.

MEHRA R. HAN B, TOMLINS SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma;molecular evidence for an independent group of diseases. Cancer Res.2007.67( 17):7991-7995.

BERG КГ). BRASSO K, THOMSEN FB, et al. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer. J Clin Pathol.2015.68( 10) :788-794.

PARK K. TOMLINS SA, MUDALIAR KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia,2010,12(7) :590-598.

UDAGER AM, SHI Y, TOMLINS SA, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, cast ration-resistant prostate cancer. Prostate,2011,7 И 12): 1199-1208.

GSPONER JR. BRAUN M, SCHEBLE VJ, et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis.2014,17(2): 126-131.

RAYMUNDO EM, DIWA MH. LAPITAN MC, et al. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos. Prostate, 2014,74(11):1079-1085.

RAWALS, YOUNG D, WILLIAMS M, et al. Low frequency of the ERG oncogene alterations in prostate cancer patients from India. J Cancer,2013 ,4(6);468-472.

KUMAR-SINHA C, TOMLINS SA, CHINNAIYAN AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008.8(7):497-511.

HERMANS KG, VAN MARION R, VAN DEKKEN H, et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor- negative prostate cancer. Cancer Res, 2006, 66 ( 22); 10658- 10663.

MERTZ KD, HORCIC M. HAILEMARIAM S, et al. Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer. Hum Pathol. 2013, 44 (12):272 7-2 735.

TENGLH, WANG C, BEGIN LR, et al. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology ,2013, 82(2) ;394-399.

PERNER S, MOSQUERA JM, DEMICHELIS F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol, 2007, 31 (6):882-888.

XU B, CHEVARIE-DAVIS M, CHEVALIER S, et al. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma:a study including 454 cases and review of the literature. Hum Pathol,2014 ,45(3):488-497.

EGUCHI FC, FARIA EF, SCAPULATEMPO NETO C, et at. The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness:a study in Brazilian patients. Sci Rep,2014(4) ;5640[2015-12-10]. doi: 10. 1038/srep05640.

TARISM, IRANI J, BLANCHET P, et al. ERG expression in prostate cancer; the prognostic paradox. Prostate,2014,74(15);1481-1487.


Refbacks

  • There are currently no refbacks.